Sclerostin Protein (SOST) (AA 24-213) (His tag)

Catalog No. ABIN2181781

Product Details

Target: Sclerostin (SOST)

Protein Type: Recombinant

Protein Characteristics: AA 24-213

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This Sclerostin protein is labelled with His tag.

Sequence: AA 24-213

Characteristics: This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 22.5 kDa. The protein migrates as 26-40 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

Purity: >90 % as determined by SDS-PAGE.

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).

References

Wu, Xu, Liu, Xu, Deng, He, Xian, Liu, Ni: "Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling." in: European review for medical and pharmacological sciences, Vol. 21, Issue 3, pp. 470-478, (2017) (PubMed).

Target Details

Target: Sclerostin (SOST)

Alternative Name: SOST (SOST Products)

Synonyms: LOC100313724 Protein, CDD Protein, VBCH Protein, 5430411E23Rik Protein, sclerostin Protein, LOC100313724 Protein, SOST Protein, Sost Protein

Background: Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

Molecular Weight: 22.3 kDa